Search results for "Glucemia"

showing 7 items of 7 documents

Patients' and physicians' preferences for type 2 diabetes mellitus treatments in Spain and Portugal: a discrete choice experiment.

2015

Objective: To assess Spanish and Portuguese patients' and physicians' preferences regarding type 2 diabetes mellitus (T2DM) treatments and the monthly willingness to pay (WTP) to gain benefits or avoid side effects. Methods: An observational, multicenter, exploratory study focused on routine clinical practice in Spain and Portugal. Physicians were recruited from multiple hospitals and outpatient clinics, while patients were recruited from eleven centers operating in the public health care system in different autonomous communities in Spain and Portugal. Preferences were measured via a discrete choice experiment by rating multiple T2DM medication attributes. Data were analyzed using the cond…

:Geographicals::Geographic Locations::Europe::Portugal [Medical Subject Headings]cardiovascular riskHbA1cendocrine system diseases:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Mass Index [Medical Subject Headings]:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hypoglycemia [Medical Subject Headings]:Disciplines and Occupations::Health Occupations::Medicine::Public Health [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]:Named Groups::Persons::Occupational Groups::Health Personnel::Physicians [Medical Subject Headings]HbA(1c)HbA:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Body Weight::Body Weight Changes::Weight Loss [Medical Subject Headings]:Diseases::Cardiovascular Diseases [Medical Subject Headings]preferences:Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings]diabetesnutritional and metabolic diseasesPeso corporalweightPérdida de peso:Health Care::Health Care Facilities Manpower and Services::Health Facilities::Ambulatory Care Facilities [Medical Subject Headings]Diabetes mellitus tipo 2:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Signs and Symptoms Digestive::Nausea [Medical Subject Headings]hypoglycemia:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models Statistical::Logistic Models [Medical Subject Headings]:Diseases::Pathological Conditions Signs and Symptoms::Signs and Symptoms::Body Weight [Medical Subject Headings]:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus Type 2 [Medical Subject Headings]:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents [Medical Subject Headings]Enfermedades cardiovascularesHipoglucemiawillingness to pay:Check Tags [Medical Subject Headings]discrete choice model
researchProduct

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

2022

AbstractThe STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes. The co-primary endpoints were the percentage change in body weight and achievement of weight loss of ≥5% at week 104. Efficacy was assessed among all randomized participants regardless of treatment discontinuation or rescue intervention. From 5 October 2018 to 1 February 2019, 304 participants were randomly assigned to semaglutide 2.4 mg (n = 152) or placebo (n = 152), 92.8% of whom completed the trial (attended t…

AdultMaleGlucagon-Like PeptideHypoglycemic AgentObesidadInvestigación médicaGeneral MedicineMiddle AgedOverweightWeight LoGeneral Biochemistry Genetics and Molecular BiologyTratamiento médicoTreatment OutcomeDouble-Blind MethodDiabetes Mellitus Type 2GlucemiaControl glucémicoFemaleObesitySettore MED/49 - Scienze Tecniche Dietetiche ApplicateHuman
researchProduct

Manejo de la hiperglucemia con fármacos no insulínicos en pacientes adultos con diabetes tipo 2

2019

Resumen: El adecuado tratamiento de la diabetes mellitus tipo 2 (DM2) incluye la alimentación saludable y el ejercicio (150 min/semana) como pilares básicos. Para el tratamiento farmacológico, la metformina es el fármaco de elección inicial, salvo contraindicación o intolerancia; en caso de mal control, se dispone de 8 familias terapéuticas (6 orales y 2 inyectables) como posibles combinaciones. Se presenta un algoritmo y unas recomendaciones para el tratamiento de la DM2. En prevención secundaria cardiovascular se recomienda asociar un inhibidor del cotransportador sodio-glucosa tipo 2 (iSGLT2) o un agonista del receptor de glucagon-like peptide-1 (arGLP1) en pacientes con obesidad. En pre…

Agonistmedicine.medical_specialtymedicine.drug_class030204 cardiovascular system & hematologyOverweight:Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet::Diabetic Diet [Medical Subject Headings]GastroenterologyDiabetes tipo 2:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]03 medical and health sciences0302 clinical medicineFármacos antidiabéticos:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Hyperglycemia [Medical Subject Headings]Internal medicineDiabetes mellitusmedicineGliclazide030212 general & internal medicineHiperglucemiaContraindicationlcsh:R5-920business.industryAntidiabetic drugs:Diseases::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus Type 2 [Medical Subject Headings]nutritional and metabolic diseases:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology Social::Life Style [Medical Subject Headings]Type 2 diabetesGeneral Medicinemedicine.diseaseSulfonylureaObesityHumanos:Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings]MetforminHyperglycemia:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hypoglycemic Agents [Medical Subject Headings]medicine.symptomlcsh:Medicine (General)Family Practicebusinessmedicine.drug
researchProduct

Total and Subtypes of Dietary Fat Intake and its Association with Components of the Metabolic Syndrome in a Mediterranean Population at High Cardiova…

2019

Background: The effect of dietary fat intake on the metabolic syndrome (MetS) and in turn on cardiovascular disease (CVD) remains unclear in individuals at high CVD risk. Objective: To assess the association between fat intake and MetS components in an adult Mediterranean population at high CVD risk. Design: Baseline assessment of nutritional adequacy in participants (n = 6560, men and women, 55&ndash

Blood GlucoseMaleMediterranean diethumanosPhysiologyÀcids grassos030204 cardiovascular system & hematologyOverweightDiet Mediterraneanchemistry.chemical_compound0302 clinical medicineRisk Factorsevaluación de riesgosMedicine030212 general & internal medicinemediana edadlípidos2. Zero hungerchemistry.chemical_classificationMetabolic Syndromeeducation.field_of_studyancianoNutrition and Dieteticsdietaresultado del tratamientofood and beveragesMiddle AgedLipidscardiovascular disease risk3. Good healthfat intakeTreatment OutcomeCardiovascular Diseasesdietary fatObesitatFemalemedicine.symptomlcsh:Nutrition. Foods and food supplyPolyunsaturated fatty acidglucosa sanguíneaMediterranean diet cardiovascular disease risk dietary fat fat intake fatty acidsLinoleic acidPopulationdislipidemiasenfermedades cardiovasculareslcsh:TX341-641Risk Assessmentfatty acidsArticle03 medical and health sciencesgrasas dietéticasMediterranean cooking:Ciencias de la Salud::Medicina preventiva [Materias Investigacion]Mediterranean dietCuina mediterràniafactores de riesgoHumansObesitycardiovascular diseaseseducationhiperglucemiaAgedDyslipidemiasbusiness.industryMalalties cardiovascularsHypertriglyceridemiamedicine.diseaseObesityDietary FatsDietCross-Sectional StudieschemistrySpainHyperglycemiaMetabolic syndromebusinessBiomarkersFood Scienceestudios transversalesNutrients
researchProduct

Effects of diabetes on the osseointegration of dental implants

2007

The increased prevalence of diabetes mellitus has become a public health problem. Hyperglycaemia entails a rise in the morbidity and mortality of these patients. Although a direct relationship with periodontal disease has already been shown, little is known about the results of dental implants in diabetics. The present paper reviews the bibliography linking the effect of diabetes on the osseointegration of implants and the healing of soft tissue. In experimental models of diabetes, a reduced level of bone-implant contact has been shown, and this can be reversed by means of treatment with insulin. Compared with the general population, a higher failure rate is seen in diabetic patients. Most …

implantimplanteUNESCO::CIENCIAS MÉDICASDiabetes Mellitusosseointegrationoseointegración:CIENCIAS MÉDICAS [UNESCO]hiperglucemiahyperglycaemia
researchProduct

Estudio farmacológico de los IPDE5 e IPDE5/NO en modelos in vitro de disfunción endotelial

2020

La morbilidad cardiovascular es la principal causa de muerte en pacientes diabéticos. La fisiopatología de estas alteraciones vasculares aun no está del todo dilucidada. La hiperglucemia, característica principal de la diabetes, exacerba las complicaciones macrovasculares y las complicaciones microvasculares como la retinopatía, la nefropatía o el pie diabético. La elevación de la glucosa en sangre conduce a una alteración de la función del endotelio, modificando algunas de sus funciones básicas como la regulación del tono y crecimiento vascular o la coagulación sanguínea. La disfunción endotelial se produce en gran medida por el estrés oxidativo y la formación de radicales libres de oxigen…

inhibidores fosfodiesterasa 5:CIENCIAS MÉDICAS ::Farmacología [UNESCO]disfunción endotelialóxido nítricohiperglucemiaangiogénesisUNESCO::CIENCIAS MÉDICAS ::Farmacologíadiabetes mellitus 2
researchProduct

Two‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5

2023

Background: The STEP 5 trial (NCT03693430) investigated once-weekly (OW) subcutaneous semaglutide 2.4 mg vs placebo for the treatment of overweight/obesity in adults over 2 years. Methods: Adults w ith B MI ≥ 3 0 k g/m2, or ≥27 kg/m2 and ≥ 1 weight-related comorbidity, without diabetes, were randomized 1:1 to semaglutide 2.4 mg OW or placebo for 104 weeks. Co-primary endpoints related to body weight (BW) changes. Control of eating questionnaire (CoEQ) was assessed in a subgroup from Canada/USA, with scores from 19 individual items grouped into 4 domains: craving control, craving for savory, craving for sweet, or positive mood. P values for exploratory CoEQ data are unadjusted for multiplici…

obesitysemaglutideNutrition and DieteticsEndocrinology Diabetes and MetabolismObesidadInvestigación médicaeating controlMedicine (miscellaneous)Settore MED/13 - Endocrinologiaobesity semaglutide craving control of eatingTratamiento médicoEndocrinologyGlucemiaSTEP 5Control glucémicoSettore MED/49 - Scienze Tecniche Dietetiche ApplicateObesity
researchProduct